Metastatic site and p53 primary tumor expression in previously untreated stage IV breast cancer patients

Anticancer Research

Volumn 19, Issue 5 C, 1999, Pages 4523-4528

  Paradiso, Angelo ^a   Tommasi, Stefania ^a   Barletta, Anna ^a   Leone, Bernardo ^b   Lacava, Juan ^b   Vellejo, Carlos ^b   Labriola, Angela ^a   Marzullo, Francesco ^a   Altieri, Rosanna ^a   Schittulli, Francesco ^a   De Lena, Mario ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b Oncology Institute ^*

Author keywords

Breast cancer; Metastasis; mib1; p53

Indexed keywords

PROTEIN P53;

ADVANCED CANCER; ARTICLE; BREAST CANCER; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS;

BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; PLEURAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; SOFT TISSUE NEOPLASMS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033404088     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. MacDonald NJ, De La Rosa A, Benedicts MA, Freije JMP, Krutsch H, Steeg PS: A serine phosphorylation of Nm23, and not its nucleoside diphosphate kinase activity, correlates suppression of tumor metastatic potential. J Biol Chem 268: 25780-25789, 1993.
2. Duffy MJ: Do proteases play a role in cancer invasion and metastasis? Eur J Clin Oncol 23: 583-589, 1987.
3. Formenti SC, Dunnington G, Uzieli B, Lenz H, Keren Rosemberg S, Silberman H, Spicer D, Denk M, Leichman G, Groshen S, Watkins K, Muggia F, Florentine B, Press M, Danenberg K, Danenberg P: Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuos infusion 5-fluorouracil and radiation therapy. Int J Rad Oncol Biol Phys 39: 1059-1068, 1997.
4. Isola J, Visakorpi T, Holli K, Kallionemi O: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. JNCI 84: 1109-1114, 1992.
5. Kirsh DG, Kastan MB: Tumor-suppressor p53: Implications for tumor development and prognosis. J Clin Oncol 16: 3158-3168, 1998.
6. Thor AD, Moore I Dan H, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen L, Mayall BH, Smith HS: Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. JNCI 84: 845-855, 1992.
7. Callahan R: p53 mutations, another breast cancer prognostic factor. JNCI 84: 826-827, 1992,
8. Anderson Tl, Borresen AL: Alterations of the TP53 gene as a potential prognostic marker in breast carcinomas: Diag Mol Pathol 4: 203-211, 1995.
9. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990.
10. Wynford-Thomas D, Blaydes J: The influence of cell context on the selection pressure for p53 mutation in human cancer: Carcinogenesis 19: 29-36, 1998.
11. Goh HS, Chan CS, Khine K, Smith DR: p53 behaviour of colorectal cancer. Lancet 344: 233-234, 1994.
12. Gasparini G, Weidner N, Maluta S, Pozza F, Boracchi P, Mezzetti M, Testolini A, Bevilacqua P: Intratumoral microvessel density and p53 protein: correlation with metastasis in head and neck squamous-cell carcinoma. Int J Cancer 55: 739-744, 1993.
13. Noguchi S, Koyama H, Kasugai T, Tsuji N, Tsuda H, Akiyama F, Motomura K Inaji H: The possible prognostic significance of p53 immunostaining status of the primary tumor in patients developing local recurrence after breast-conserving therapy. Oncology 55: 450-455, 1998.
14. Elledge R, Clark G, Allred D: Metastatic distribution of breast cancer and survival after first recurrence, according to p53 status. Abs in 21St Annua San Antonio Breast Cancer Symposium, 1998.
15. Fisher ER, Gregorio RM, Fisher B et al: The pathology of invasive breast cancer: a syllabus derived from findings of the NSABP. Cancer 36: 1-85, 1975.
16. Paradiso A, Rabinovich M, Vallejo C, Machiavelli M, Romero A, Perez J et al: p53 and PCNA expression in advanced colorectal cancer. Response to chemotherapy and longterm prognosis. Int J Cancer 69: 437-441, 1996 .
17. De Lena M, Barletta A, Marzullo F, Rabinovich M, Leone B, Vallejo C et al: Nuclear grade and DNA ploidy in stage IV breast cancer with only visceral metastasis at initial diagnosis. Tumori 82: 386-389, 1996.
18. Shackney S, Pollice A, Sweeney L, Yakulis R, Wolmark N, Smith C: Genetic evolutionary staging in invasive human breast cancer: the p53 ▶Her-2/ neu ▶ ras sequence. Proc AACR 39: 124, 1998, abs 844.
19. Heide I, Theide C, Sonntag T, De Kant E, Neubauer A, Jonas S, Peter FJ, Neuhaus P, Herrmann R, Huhn D, Rochlitz CF: The status of p53 in the metastatic progression of colorectal cancer. Eur J Cancer 33: 1314-1322, 1997.
20. Shiota G, Ishida M, Noguchi N, Takano Y, Oyama K, Okubo M, Katayama S, Harada K, Hori K, Ashida K, Kishimoto Y, Hosoda A, Suou T, Ito H Kawasaki H: Clinical significance of serum p53 antibody in patients with gastric cancer. Res Commun Mol Pathol Pharmacol 99: 41-51, 1998.
21. Diel I J, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G: Reduction in new metastases in breast cancer with adjuvant clodronate treatment.N Engl J Med 339: 357-363, 1998.
22. De Lena M, Romero A, Rabinovich M, Leone B, Vallejo C, Machiavelli M et al: Metastatic pattern and DNA ploidy in stage IV breast cancer at initial diagnosis. Am J Clin Oncol 16: 245-249, 1993.
23. Hall PA, Lane DP: p53 in tumor pathology: can we trust immunohistochemistry? J Pathol 172: 1-4, 1994.
24. Sjogren S, Inganas M, Norberg T, Lindgren A, Nordgren H, Holmberg L, Bergh J: The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunochemistry. JNCI 88: 173-182, 1996.
25. Greenblatt MS, Bennet WP7 Hollstein M, Harris CC: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994.
26. Allred DC, Clark GM7 Fuqua SAW, Elledge RM, Hilsenbeck SG, Ravdin PM, Yee D, Chamness GC, Osborne CK: Overexpression of p53 in node-positive breast cancer. Breast Cancer Res Treat 27: 131, 1993.
27. Riou G, Le MG, Travagli JP, Levine AJ, Moll UM: Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. JNCI 85: 1765-1767, 1993.
28. Linn SC, Honkoop AH, Hoekman K, VanderValk P, Pinedo HM, Giaccone G: p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Br J Cancer 74: 63-68, 1996.
29. Honkoop AH, vanDiest PJ, deJong JS, Linn SC, Giaccone G, Hoekman K, Wagstaff J, Pinedo HM: Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 77: 621-626, 1998.
30. Elledge RM, Clark GM, Fuqua SA, Yu Yi-Yang, Allred DC: p53 Protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. Cancer Res 54: 3752-3757, 1994.